Two Sigma Investments LP Buys 320,614 Shares of ProQR Therapeutics (NASDAQ:PRQR)

Two Sigma Investments LP grew its position in ProQR Therapeutics (NASDAQ:PRQR - Free Report) by 512.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 383,134 shares of the biopharmaceutical company's stock after buying an additional 320,614 shares during the quarter. Two Sigma Investments LP owned 0.47% of ProQR Therapeutics worth $1,015,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Point72 Asset Management L.P. bought a new stake in shares of ProQR Therapeutics during the fourth quarter worth about $3,952,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in shares of ProQR Therapeutics in the 4th quarter valued at $602,000. Millennium Management LLC increased its stake in ProQR Therapeutics by 1,864.4% in the fourth quarter. Millennium Management LLC now owns 2,827,280 shares of the biopharmaceutical company's stock valued at $7,492,000 after purchasing an additional 2,683,351 shares in the last quarter. DAFNA Capital Management LLC raised its stake in ProQR Therapeutics by 73.1% during the 4th quarter. DAFNA Capital Management LLC now owns 1,567,561 shares of the biopharmaceutical company's stock worth $4,154,000 after buying an additional 661,979 shares during the period. Finally, Cubist Systematic Strategies LLC acquired a new position in shares of ProQR Therapeutics during the fourth quarter worth approximately $354,000. 32.65% of the stock is currently owned by institutional investors.

ProQR Therapeutics Stock Performance

ProQR Therapeutics stock opened at $1.79 on Friday. The firm's fifty day moving average price is $1.49 and its 200-day moving average price is $2.16. ProQR Therapeutics has a fifty-two week low of $1.07 and a fifty-two week high of $4.62. The stock has a market cap of $188.33 million, a P/E ratio of -5.59 and a beta of 0.35.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.02). The business had revenue of $4.89 million for the quarter, compared to analysts' expectations of $4.90 million. ProQR Therapeutics had a negative return on equity of 71.58% and a negative net margin of 134.31%. On average, analysts predict that ProQR Therapeutics will post -0.31 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on PRQR shares. Chardan Capital reaffirmed a "buy" rating and issued a $4.00 price target on shares of ProQR Therapeutics in a research report on Friday, March 14th. Cantor Fitzgerald began coverage on shares of ProQR Therapeutics in a report on Tuesday, April 29th. They set an "overweight" rating and a $8.00 price objective for the company. Evercore ISI assumed coverage on ProQR Therapeutics in a research report on Tuesday, April 29th. They issued an "outperform" rating and a $5.00 target price for the company. Citigroup raised shares of ProQR Therapeutics from a "neutral" rating to a "buy" rating and set a $4.00 price target on the stock in a research report on Monday, March 10th. Finally, Oppenheimer reduced their target price on ProQR Therapeutics from $15.00 to $9.00 and set an "outperform" rating for the company in a report on Tuesday, May 13th. One investment analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $8.00.

ProQR Therapeutics Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.